Human serum albumin, systemic inflammation, and cirrhosis.

[1]  M. Poca,et al.  Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. , 2014, Journal of hepatology.

[2]  M. Pavesi,et al.  Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). , 2014, Journal of hepatology.

[3]  J. Kellum,et al.  A Unified Theory of Sepsis-Induced Acute Kidney Injury: Inflammation, Microcirculatory Dysfunction, Bioenergetics, and the Tubular Cell Adaptation to Injury , 2014, Shock.

[4]  G. Ghiggeri,et al.  Oxidized albumin. The long way of a protein of uncertain function. , 2013, Biochimica et biophysica acta.

[5]  W. Bal,et al.  Binding of transition metal ions to albumin: sites, affinities and rates. , 2013, Biochimica et biophysica acta.

[6]  T. Amisaki,et al.  Fatty acid binding to serum albumin: molecular simulation approaches. , 2013, Biochimica et biophysica acta.

[7]  Toru Maruyama,et al.  Albumin-drug interaction and its clinical implication. , 2013, Biochimica et biophysica acta.

[8]  J. Rose,et al.  Structural studies of several clinically important oncology drugs in complex with human serum albumin. , 2013, Biochimica et biophysica acta.

[9]  Daichang Yang,et al.  Human serum albumin from recombinant DNA technology: challenges and strategies. , 2013, Biochimica et biophysica acta.

[10]  Leslie R Evans,et al.  Albumin as a versatile platform for drug half-life extension. , 2013, Biochimica et biophysica acta.

[11]  M. Otagiri,et al.  Redox properties of serum albumin. , 2013, Biochimica et biophysica acta.

[12]  J. Hayashi,et al.  Glycated albumin and diabetes mellitus. , 2013, Biochimica et biophysica acta.

[13]  U. Kragh-Hansen,et al.  Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes. , 2013, Biochimica et biophysica acta.

[14]  N. Bhagavan,et al.  Novel insights into the pleiotropic effects of human serum albumin in health and disease. , 2013, Biochimica et biophysica acta.

[15]  M. Singer.  The role of mitochondrial dysfunction in sepsis-induced multi-organ failure , 2013, Virulence.

[16]  R. Stauber,et al.  Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. , 2013, Journal of hepatology.

[17]  D. Shawcross,et al.  Inflammation and hepatic encephalopathy. , 2013, Archives of biochemistry and biophysics.

[18]  R. Moreau,et al.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.

[19]  D. Shawcross,et al.  Systemic inflammation and ammonia in hepatic encephalopathy , 2013, Metabolic Brain Disease.

[20]  J. Mira,et al.  Specific antioxidant properties of human serum albumin , 2013, Annals of Intensive Care.

[21]  R. Navickis,et al.  Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  P. Angeli,et al.  Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms , 2013, Hepatology.

[23]  B. Sharma,et al.  Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[24]  M. Trauner,et al.  Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis , 2012, Hepatology.

[25]  M. Pavesi,et al.  Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. , 2012, Journal of hepatology.

[26]  K. Tracey,et al.  Alarmins: awaiting a clinical response. , 2012, The Journal of clinical investigation.

[27]  E. Reisinger,et al.  Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  V. Trezza,et al.  Human serum albumin: from bench to bedside. , 2012, Molecular aspects of medicine.

[29]  Virendra Singh,et al.  Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. , 2012, Journal of hepatology.

[30]  J. Weiss,et al.  Endotoxin·albumin complexes transfer endotoxin monomers to MD-2 resulting in activation of TLR4 , 2012, Innate immunity.

[31]  M. Pavesi,et al.  Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. , 2012, Journal of hepatology.

[32]  P. Caraceni,et al.  Albumin infusion in patients undergoing large‐volume paracentesis: A meta‐analysis of randomized trials , 2012, Hepatology.

[33]  J. Córdoba,et al.  Liver-induced inflammation hurts the brain. , 2012, Journal of hepatology.

[34]  B. Sharma,et al.  27 SERUM ENDOTOXINS AND INFLAMMATORY MEDIATORS IN PATIENTS WITH CIRRHOSIS AND HEPATIC ENCEPHALOPATHY , 2012 .

[35]  P. Nietert,et al.  Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  V. Hilser,et al.  Structural Dynamics, Intrinsic Disorder, and Allostery in Nuclear Receptors as Transcription Factors* , 2011, The Journal of Biological Chemistry.

[37]  V. Arroyo,et al.  Management of hepatorenal syndrome in patients with cirrhosis , 2011, Nature Reviews Nephrology.

[38]  Arun J. Sanyal,et al.  Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. , 2011, Journal of hepatology.

[39]  D. Bailey,et al.  Neuro-oxidative-nitrosative stress in sepsis , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  H. Galley.  Oxidative stress and mitochondrial dysfunction in sepsis. , 2011, British journal of anaesthesia.

[41]  G. Auzinger,et al.  Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. , 2011, Journal of hepatology.

[42]  Gerene M Denning,et al.  Low level bacterial endotoxin activates two distinct signaling pathways in human peripheral blood mononuclear cells , 2011, Journal of Inflammation.

[43]  R. Wiest.  Role of sympathetic nervous activity for bacterial translocation in advanced experimental liver cirrhosis , 2011 .

[44]  G. Melacini,et al.  Stoichiometry and affinity of the human serum albumin-Alzheimer's Aβ peptide interactions. , 2011, Biophysical journal.

[45]  J. Andersen,et al.  Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain* , 2010, The Journal of Biological Chemistry.

[46]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[47]  S. Møller.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. , 2010, Journal of hepatology.

[48]  H. Galley.  Bench-to-bedside review: Targeting antioxidants to mitochondria in sepsis , 2010, Critical care.

[49]  R. Hughes,et al.  Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. , 2010, World journal of gastroenterology.

[50]  S. Akira,et al.  Pattern Recognition Receptors and Inflammation , 2010, Cell.

[51]  V. Arroyo,et al.  Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome , 2010, Hepatology.

[52]  I. Sandlie,et al.  Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding* , 2009, The Journal of Biological Chemistry.

[53]  A. Krag,et al.  Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites , 2009, Gut.

[54]  Roger Williams,et al.  Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality , 2009, Hepatology.

[55]  G. Garcia‐Tsao,et al.  Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program , 2009, The American Journal of Gastroenterology.

[56]  G. Pariani,et al.  Allosteric and binding properties of Asp1–Glu382 truncated recombinant human serum albumin – an optical and NMR spectroscopic investigation , 2009, The FEBS journal.

[57]  P. Angeli,et al.  175 TERLIPRESSIN GIVEN AS CONTINUOUS INTRAVENOUS INFUSION VERSUS TERLIPRESSIN GIVEN AS INTRAVENOUS BOLUSES IN THE TREATMENT OF TYPE 1 HEPATORENAL SYNDROME (HRS) IN PATIENTS WITH CIRRHOSIS , 2009 .

[58]  V. Felipo,et al.  IL-6 and IL-18 in Blood May Discriminate Cirrhotic Patients With and Without Minimal Hepatic Encephalopathy , 2009, Journal of clinical gastroenterology.

[59]  F. Zijlstra,et al.  High interleukin-6 production within the peritoneal cavity in decompensated cirrhosis and malignancy-related ascites. , 2008, Liver.

[60]  S. Sarin,et al.  An Open Label, Pilot, Randomized Controlled Trial of Noradrenaline Versus Terlipressin in the Treatment of Type 1 Hepatorenal Syndrome and Predictors of Response , 2008, The American Journal of Gastroenterology.

[61]  A. Sanyal,et al.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. , 2008, Gastroenterology.

[62]  M. Rizzetto,et al.  Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. , 2007, Journal of hepatology.

[63]  M. Navasa,et al.  Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. , 2007, Gastroenterology.

[64]  M. Merx,et al.  Sepsis and the heart. , 2007, Circulation.

[65]  C. Zwingmann,et al.  Endotoxemia produces coma and brain swelling in bile duct ligated rats , 2007, Hepatology.

[66]  S. Mitzner,et al.  Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease , 2007, European journal of gastroenterology & hepatology.

[67]  P. Angeli,et al.  Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features , 2007, Hepatology.

[68]  R. Groszmann,et al.  The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule , 2006, Hepatology.

[69]  J. Vinel,et al.  Treatment of Hepatorenal Syndrome as Defined by the International Ascites Club by Albumin and Furosemide Infusion According to the Central Venous Pressure: A Prospective Pilot Study , 2005, The American Journal of Gastroenterology.

[70]  M. Navasa,et al.  Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. , 2005, Gastroenterology.

[71]  H. Fukui.  Relation of endotoxin, endotoxin binding proteins and macrophages to severe alcoholic liver injury and multiple organ failure. , 2005, Alcoholism, clinical and experimental research.

[72]  S. Curry,et al.  Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.

[73]  W. Jiménez,et al.  A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis , 2005, Hepatology.

[74]  W. Jiménez,et al.  Circulatory function and hepatorenal syndrome in cirrhosis , 2005, Hepatology.

[75]  E. Bourdon,et al.  Differential effects of cysteine and methionine residues in the antioxidant activity of human serum albumin , 2005, Free radical research.

[76]  W. Jiménez,et al.  Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. , 2004, Journal of hepatology.

[77]  V. Arroyo,et al.  Management of cirrhosis and ascites. , 2004, The New England journal of medicine.

[78]  M. Odeh,et al.  Serum levels of tumor necrosis factor‐α correlate with severity of hepatic encephalopathy due to chronic liver failure , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[79]  W. Jiménez,et al.  High-density lipoproteins reduce the effect of endotoxin on cytokine production and systemic hemodynamics in cirrhotic rats with ascites. , 2004, Journal of hepatology.

[80]  Roger Williams,et al.  Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. , 2004, Journal of hepatology.

[81]  W. Jiménez,et al.  Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis , 2003, Hepatology.

[82]  J. Calleja,et al.  Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement , 2003, Hepatology.

[83]  J. Weiss,et al.  An Essential Role for Albumin in the Interaction of Endotoxin with Lipopolysaccharide-binding Protein and sCD14 and Resultant Cell Activation* , 2002, The Journal of Biological Chemistry.

[84]  M. Rizzetto,et al.  Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2 , 2002, European journal of gastroenterology & hepatology.

[85]  R. Bataller,et al.  Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study , 2002, Hepatology.

[86]  E. Nudler,et al.  Catalysis of S-nitrosothiols formation by serum albumin: The mechanism and implication in vascular control , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[87]  M. Koch,et al.  Investigation into the interaction of recombinant human serum albumin with Re-lipopolysaccharide and lipid A , 2002, Journal of endotoxin research.

[88]  R. Moreau,et al.  Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. , 2002, Gastroenterology.

[89]  N. Bhagavan,et al.  Structural insights into human serum albumin‐mediated prostaglandin catalysis , 2002, Protein science : a publication of the Protein Society.

[90]  A. Malik,et al.  Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function , 2002, Histochemistry and Cell Biology.

[91]  A. Nesbitt,et al.  Prolonged in vivo residence times of antibody fragments associated with albumin. , 2001, Bioconjugate chemistry.

[92]  A. Gunasekera,et al.  Expression, refolding, and isotopic labeling of human serum albumin domains for NMR spectroscopy. , 2000, Protein expression and purification.

[93]  S. Curry,et al.  Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. , 2000, Journal of molecular biology.

[94]  A. Cantin,et al.  Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation. , 2000, American journal of respiratory and critical care medicine.

[95]  J. Feix,et al.  A Dynamic Model for Bilirubin Binding to Human Serum Albumin* , 2000, The Journal of Biological Chemistry.

[96]  R. Bataller,et al.  Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. , 2000, Journal of hepatology.

[97]  R. Groszmann,et al.  Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. , 1999, The Journal of clinical investigation.

[98]  M. Navasa,et al.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. , 1999, The New England journal of medicine.

[99]  M. Pinzani,et al.  Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. , 1999, Journal of hepatology.

[100]  A. Gadano,et al.  Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. , 1999, Journal of hepatology.

[101]  R. Bataller,et al.  Increased cerebrovascular resistance in cirrhotic patients with ascites , 1998, Hepatology.

[102]  L. Molina,et al.  Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. , 1998, Journal of hepatology.

[103]  W. Jiménez,et al.  Tumor necrosis factor and interleukin‐6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality , 1998, Hepatology.

[104]  W. Jiménez,et al.  Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion , 1998, Hepatology.

[105]  R. Bataller,et al.  Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. , 1997, Journal of hepatology.

[106]  E. Stadtman,et al.  Protein Oxidation in Aging, Disease, and Oxidative Stress* , 1997, The Journal of Biological Chemistry.

[107]  W. Jiménez,et al.  Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. , 1997, Gastroenterology.

[108]  W. Jiménez,et al.  Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. , 1996, Gastroenterology.

[109]  Shou-Dong Lee,et al.  Plasma interleukin‐8 levels in patients with post‐hepatitic cirrhosis: Relationship to severity of liver disease, portal hypertension and hyperdynamic circulation , 1996, Journal of gastroenterology and hepatology.

[110]  P. Mannucci,et al.  High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia , 1996, Hepatology.

[111]  S. D. Lee,et al.  Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. , 1996, Scandinavian journal of gastroenterology.

[112]  O. Moine,et al.  Plasma endotoxin and tumor necrosis factor-α in the hyperkinetic state of cirrhosis , 1995 .

[113]  P. Balaram,et al.  Characterization of the interaction of lipid A and lipopolysaccharide with human serum albumin: implications for an endotoxin carrier function for albumin , 1995 .

[114]  D. Bagchi,et al.  Oxidative mechanisms in the toxicity of metal ions. , 1995, Free radical biology & medicine.

[115]  J. Llovet,et al.  Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis , 1994, Hepatology.

[116]  R. Dziarski.  Cell-bound albumin is the 70-kDa peptidoglycan-, lipopolysaccharide-, and lipoteichoic acid-binding protein on lymphocytes and macrophages. , 1994, The Journal of biological chemistry.

[117]  R. Stocker,et al.  Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. , 1994, The Journal of biological chemistry.

[118]  P. Oh,et al.  Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. , 1994, The Journal of biological chemistry.

[119]  D. C. Carter,et al.  Atomic structure and chemistry of human serum albumin , 1993, Nature.

[120]  W. Jiménez,et al.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.

[121]  E. Dupont,et al.  Tumor necrosis factor α and interleukin 6 plasma levels in infected cirrhotic patients , 1993 .

[122]  J. Schnitzer,et al.  High affinity binding, endocytosis, and degradation of conformationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors. , 1993, The Journal of biological chemistry.

[123]  R. Horvat,et al.  Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified albumins. Presence in many cells and tissues with a possible role in catabolism. , 1992, The Journal of biological chemistry.

[124]  H. Tilg,et al.  Serum levels of cytokines in chronic liver diseases. , 1992, Gastroenterology.

[125]  V. Arroyo,et al.  Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. , 1991, The New England journal of medicine.

[126]  J. Llach,et al.  Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. , 1990, Gastroenterology.

[127]  D C Carter,et al.  Three-dimensional structure of human serum albumin. , 1989, Science.

[128]  S. J. Burton,et al.  Refolding human serum albumin at relatively high protein concentration. , 1989, European journal of biochemistry.

[129]  Vicente Arroyo,et al.  Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis , 1988, Hepatology.

[130]  N. Simionescu,et al.  Identification of albumin-binding proteins in capillary endothelial cells , 1988, The Journal of cell biology.

[131]  J. Llach,et al.  Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. , 1988, Gastroenterology.

[132]  W. Jiménez,et al.  Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. , 1987, Gastroenterology.

[133]  W. Jiménez,et al.  Comparison of Paracentesis and Diuretics in the Treatment of Cirrhotics With Tense Ascites , 1987 .

[134]  B. Groves,et al.  Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients. , 1985, Kidney international.

[135]  F. Fitzpatrick,et al.  Albumin-eicosanoid interactions. A model system to determine their attributes and inhibition. , 1984, The Journal of biological chemistry.

[136]  M. A. Wynalda,et al.  Albumins stabilize prostaglandin I2. , 1980, Prostaglandins.

[137]  H. Leveen,et al.  Renal failure in ascites secondary to hepatic, renal, and pancreatic disease. Treatment with a LeVeen peritoneovenous shunt. , 1978, Archives of surgery.

[138]  E. Granström,et al.  Albumin stabilizes thromboxane A2 , 1977, FEBS letters.

[139]  A. Hvidt,et al.  Conformational changes in human serum albumin as revealed by hydrogen-deuterium exchange studies. , 1972, The Journal of biological chemistry.

[140]  P. Vesin,et al.  [INTRAVENOUS ALBUMIN LOADING IN ASCITIC CIRRHOSIS. BIOLOGICAL STUDY]. , 1964, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[141]  L. Oliver.  The contributions of surgery to the treatment and understanding of parkinsonism. , 1958, Lancet.

[142]  S. Sherlock,et al.  Electrolyte and circulatory changes in terminal liver failure. , 1956, Lancet.

[143]  C. S. Davidson,et al.  AN EVALUATION OF HUMAN SERUM ALBUMIN IN THE TREATMENT OF CIRRHOSIS OF THE LIVER. , 1949, The Journal of clinical investigation.

[144]  H. Kunkel,et al.  THE USE OF CONCENTRATED HUMAN SERUM ALBUMIN IN THE TREATMENT OF CIRRHOSIS OF THE LIVER. , 1948, The Journal of clinical investigation.

[145]  J. Stokes,et al.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XI. THE USE OF CONCENTRATED NORMAL HUMAN SERUM GAMMA GLOBULIN (HUMAN IMMUNE SERUM GLOBULIN) IN THE PROPHYLAXIS AND TREATMENT OF MEASLES. , 1944, The Journal of clinical investigation.

[146]  M. Geuking,et al.  Pathological bacterial translocation in liver cirrhosis. , 2014, Journal of hepatology.

[147]  G. Marsche,et al.  Redox state of human serum albumin in terms of cysteine-34 in health and disease. , 2010, Methods in enzymology.

[148]  A. Malik.  Targeting endothelial cell surface receptors: novel mechanisms of microvascular endothelial barrier transport , 2009, Hamdan Medical Journal.

[149]  G. J. van der Vusse.  Albumin as fatty acid transporter. , 2009, Drug metabolism and pharmacokinetics.

[150]  Gyeong a Kim,et al.  Terlipressin and Albumin vs Albumin in Patients with Cirrhosis and Hepatorenal Syndrome: A Randomized Study , 2008 .

[151]  G. J. Vusse.  Albumin as Fatty Acid Transporter , 2008 .

[152]  R. Groszmann,et al.  Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis , 1999, American Journal of Gastroenterology.

[153]  J. Devière,et al.  Plasma endotoxin and tumor necrosis factor-alpha in the hyperkinetic state of cirrhosis. , 1995, Journal of hepatology.

[154]  V. Arroyo,et al.  A European survey on the treatment of ascites in cirrhosis. , 1994, Journal of hepatology.

[155]  E. Dupont,et al.  Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. , 1993, Gastroenterology.

[156]  J. Llach,et al.  Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. , 1990, Gastroenterology.

[157]  K. Tarao,et al.  Influence of long-term administration of serum albumin on the prognosis of liver cirrhosis in man. , 1983, The Tokai journal of experimental and clinical medicine.

[158]  V. Davenport,et al.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XXXI. THE USE OF SALT-POOR CONCENTRATED HUMAN SERUM ALBUMIN SOLUTION IN THE TREATMENT OF HEPATIC CIRRHOSIS. , 1946, Journal of Clinical Investigation.